Sansone N, Boschiero M, Marson F
Biomedicines. 2024; 12(10).
PMID: 39457519
PMC: 11505156.
DOI: 10.3390/biomedicines12102206.
Liu C, Leighow S, McIlroy K, Lu M, Dennis K, Abello K
Cell Rep Med. 2023; 4(10):101227.
PMID: 37852183
PMC: 10591048.
DOI: 10.1016/j.xcrm.2023.101227.
Neuberger A, Sobolevsky A
Channels (Austin). 2023; 17(1):2266669.
PMID: 37838981
PMC: 10578198.
DOI: 10.1080/19336950.2023.2266669.
Maziarz M, Stencel A
Hist Philos Life Sci. 2022; 44(4):47.
PMID: 36258007
PMC: 9579070.
DOI: 10.1007/s40656-022-00532-9.
Xu X, Qian X, Gao C, Pang Y, Zhou H, Zhu L
Front Microbiol. 2022; 13:953846.
PMID: 36003932
PMC: 9393627.
DOI: 10.3389/fmicb.2022.953846.
Drug repurposing: a systematic review on root causes, barriers and facilitators.
Krishnamurthy N, Grimshaw A, Axson S, Choe S, Miller J
BMC Health Serv Res. 2022; 22(1):970.
PMID: 35906687
PMC: 9336118.
DOI: 10.1186/s12913-022-08272-z.
Repurposing FDA approved drugs as possible anti-SARS-CoV-2 medications using ligand-based computational approaches: sum of ranking difference-based model selection.
De P, Kumar V, Kar S, Roy K, Leszczynski J
Struct Chem. 2022; 33(5):1741-1753.
PMID: 35692512
PMC: 9171098.
DOI: 10.1007/s11224-022-01975-3.
Overcoming Therapy Resistance in Colon Cancer by Drug Repurposing.
El Zarif T, Yibirin M, De Oliveira-Gomes D, Machaalani M, Nawfal R, Bittar G
Cancers (Basel). 2022; 14(9).
PMID: 35565237
PMC: 9099737.
DOI: 10.3390/cancers14092105.
α-Asarone Attenuates Osteoclastogenesis and Prevents Against Oestrogen-Deficiency Induced Osteoporosis.
Tian H, Jiang T, Yang K, Ning R, Wang T, Zhou Q
Front Pharmacol. 2022; 13:780590.
PMID: 35370648
PMC: 8971932.
DOI: 10.3389/fphar.2022.780590.
Repurposable drugs for SARS-CoV-2 and influenza sepsis with scRNA-seq data targeting post-transcription modifications.
Wang Z, Guo K, Gao P, Pu Q, Li C, Hur J
Precis Clin Med. 2022; 4(4):215-230.
PMID: 34993416
PMC: 8694063.
DOI: 10.1093/pcmedi/pbab022.
Editorial: Repurposed Drugs Targeting Cancer Signaling Pathways: Dissecting New Mechanism of Action Through and Analyses.
Lopez-Urrutia E, Padilla-Benavides T, Perez-Plasencia C, Campos-Parra A
Front Oncol. 2021; 11:773429.
PMID: 34671566
PMC: 8521020.
DOI: 10.3389/fonc.2021.773429.
Using the drug repositioning approach to develop a novel therapy, tipepidine hibenzate sustained-release tablet (TS-141), for children and adolescents with attention-deficit/hyperactivity disorder.
Saito T, Yamashita Y, Tomoda A, Okada T, Umeuchi H, Iwamori S
BMC Psychiatry. 2020; 20(1):530.
PMID: 33167920
PMC: 7653993.
DOI: 10.1186/s12888-020-02932-2.
Current Status of COVID-19 Therapies and Drug Repositioning Applications.
Altay O, Mohammadi E, Lam S, Turkez H, Boren J, Nielsen J
iScience. 2020; 23(7):101303.
PMID: 32622261
PMC: 7305759.
DOI: 10.1016/j.isci.2020.101303.
Clinical trials on drug repositioning for COVID-19 treatment.
Viveiros Rosa S, Santos W
Rev Panam Salud Publica. 2020; 44:e40.
PMID: 32256547
PMC: 7105280.
DOI: 10.26633/RPSP.2020.40.
Repurposing Drugs for Acute Myeloid Leukemia: A Worthy Cause or a Futile Pursuit?.
Wojcicki A, Kadapakkam M, Frymoyer A, Lacayo N, Chae H, Sakamoto K
Cancers (Basel). 2020; 12(2).
PMID: 32069925
PMC: 7072462.
DOI: 10.3390/cancers12020441.
Drug repurposing for breast cancer therapy: Old weapon for new battle.
Aggarwal S, Verma S, Aggarwal S, Gupta S
Semin Cancer Biol. 2019; 68:8-20.
PMID: 31550502
PMC: 7128772.
DOI: 10.1016/j.semcancer.2019.09.012.
Prediction of Potential Drug-Disease Associations through Deep Integration of Diversity and Projections of Various Drug Features.
Xuan P, Song Y, Zhang T, Jia L
Int J Mol Sci. 2019; 20(17).
PMID: 31443472
PMC: 6747548.
DOI: 10.3390/ijms20174102.
Convolutional Neural Network and Bidirectional Long Short-Term Memory-Based Method for Predicting Drug-Disease Associations.
Xuan P, Ye Y, Zhang T, Zhao L, Sun C
Cells. 2019; 8(7).
PMID: 31336774
PMC: 6679344.
DOI: 10.3390/cells8070705.
